Newsroom | 67888 results

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference F...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectoryY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today the appointment of Kevin Pojasek, Ph.D., to its Board of Directors. Dr. Pojasek brings more than two decades of expertise founding, scaling, and leading innovative biopharma companies, with deep expertise across corporate strategy, business development, and research and development. Dr. Pojasek is currently president and chief executive officer of...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman and CEO of IQVIA. "We delivered near double digit revenue and EPS growth, and the strongest...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the pioneer in translating real-world clinical data into personalized real-world evidence (RWE), announced the addition of two new hires to the leadership team, including the company's first Chief Technology Officer and Chief Financial Officer. The addition of these two team members expands the companies’ domain knowledge across the healthcare ecosystem including telehealth, payers and big tech. To further enhance the company's mission to clos...

SHEFFIELD, England--(BUSINESS WIRE)--SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the launch of its Liver.SET™ library of liver-specific synthetic promoters. Developed using SynGenSys’ proprietary informatics and computational design platform, the Liver.SET library comprises a range of compact, patentable synthetic promoters for liver-targeted...

HYOGO, Japan--(BUSINESS WIRE)--JCR announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies at the WORLDSymposium 2026....

威斯康辛州麥迪森--(BUSINESS WIRE)--(美國商業資訊)-- 中國國家藥品監督管理局(NMPA)已核准OncoMate® 微衛星不穩定性(MSI)檢測試劑盒為中國三類體外診斷醫療器材。該試劑盒擬做為伴隨診斷試劑，用於辨識高微衛星不穩定性(MSI-H)實質腫瘤病患，以接受美國紐澤西州拉威市Merck & Co., Inc.的抗PD-1療法——KEYTRUDA® (pembrolizumab)治療。這是Promega首款獲得NMPA核准的伴隨診斷試劑。 Promega全球臨床市場總監Alok Sharma表示：「此次核准代表中國在實現更具個人化、更有效的癌症治療方面邁出了重要一步。我們很驕傲能與製藥企業合作，提供全球解決方案，擴大創新技術和挽救生命的有效療法的可及性。」 中國仍是全球癌症負擔最重的國家之一，實質腫瘤占全國癌症確診病例的絕大多數。儘管腫瘤治療領域取得了諸多進展，但大多數晚期實質腫瘤病患在一線治療後最終仍會出現疾病惡化，因此迫切需要能指導更有效的替代治療策略的工具。OncoMate® MSI檢測試劑盒是一種以聚合酶鏈反應(PCR)技術為基礎的檢測方法，旨在...

威斯康星州麦迪逊--(BUSINESS WIRE)--(美国商业资讯)-- 中国国家药品监督管理局(NMPA)已批准OncoMate® 微卫星不稳定性(MSI)检测试剂盒作为中国三类体外诊断医疗器械。该试剂盒拟作为伴随诊断试剂，用于识别高微卫星不稳定性(MSI-H)实体瘤患者，以接受美国新泽西州拉威市Merck & Co., Inc.的抗PD-1疗法——KEYTRUDA® (pembrolizumab)治疗。这是Promega首款获得NMPA批准的伴随诊断试剂。 Promega全球临床市场总监Alok Sharma表示：“此次批准标志着中国在实现更具个性化、更有效的癌症治疗方面迈出了重要一步。我们很自豪能与制药企业合作，提供全球解决方案，扩大创新技术和挽救生命的有效疗法的可及性。” 中国仍是全球癌症负担最重的国家之一，实体瘤占全国癌症确诊病例的绝大多数。尽管肿瘤治疗领域取得了诸多进展，但大多数晚期实体瘤患者在一线治疗后最终仍会出现疾病进展，因此迫切需要能指导更有效的替代治疗策略的工具。OncoMate® MSI检测试剂盒是一种基于聚合酶链反应(PCR)技术的检测方法，旨在评估肿...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We...

LEMONT, Ill.--(BUSINESS WIRE)--Three collaborative projects aim to streamline AI deployment in nuclear facilities....